NEW YORK , March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany.
With the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective option in the form of pills. The weight loss drug market, projected by Goldman Sachs to reach $130 billion by 2030, represents a significant opportunity for drugmakers.
– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activation s in Preclinical Models – – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – NEW YORK , Feb. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data on its lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, taking place from February 27 to March 1, in West Palm Beach, Florida. "Having two poster presentations on vidofludimus calcium at the prestigious ACTRIMS Forum highlights the unique importance of our drug candidate and its promise as a potential new treatment option for multiple sclerosis (MS)," stated Daniel Vitt, Ph.D.
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive to discuss the company's latest findings on IMU-856, a drug candidate initially studied for celiac disease. New data suggests that IMU-856 significantly increases endogenous GLP-1 levels in a dose-dependent manner, which could make it a potential oral treatment for obesity.
Immunic Inc (NASDAQ:IMUX) has released new data that supports the potential of its investigational therapeutic IMU-856 as an oral treatment for weight management. IMU-856, a small molecule that targets SIRT6, demonstrated a dose-dependent increase in endogenous glucagon-like peptide-1 (GLP-1) levels in a post hoc analysis of patients from a phase 1b clinical trial in celiac disease.
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February: February 10-11: BIO CEO & Investor Conference 2025. Daniel Vitt, Ph.D.
Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company's progress in advancing its novel therapy vidofludimus calcium. He discussed the significant milestones achieved in 2024, such as the positive interim analysis of the ENSURE trials in relapsing multiple sclerosis (MS) and the anticipation of the results from the CALLIPER progressive MS study in April 2025.
Immunic Inc (NASDAQ:IMUX) has reflected on key milestones achieved in 2024, including advancing its novel therapy, vidofludimus calcium, toward key data readouts and securing significant funding to progress its clinical programs. In a statement, the company said it expects top-line data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (PMS) in April 2025.
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today highlighted its 2024 accomplishments and upcoming milestones. "The past year was marked by substantial progress for our orally available lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), as we continued to advance both our phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and our twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS)," stated Daniel Vitt, Ph.D.
NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the Piper Sandler 36th Annual Healthcare Conference, taking place December 3-5, 2024, in New York.